收稿日期: 2021-04-14
网络出版日期: 2021-12-25
基金资助
甘肃省创新基地和人才计划(21JR7RA015)
寇明坤, 徐娜娜, 石静云, 吴涛 . 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021 , 20(06) : 588 -591 . DOI: 10.16150/j.1671-2870.2021.06.015
| [1] | Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma[J]. Blood Cancer J, 2019, 9(4):44. |
| [2] | Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma[J]. Dtsch Arztebl Int, 2016, 113(27-28):470-476. |
| [3] | Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. |
| [4] | Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv52-iv61. |
| [5] | Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma[J]. Ther Adv Hematol, 2018, 9(5):123-133. |
| [6] | Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma[J]. Memo, 2018, 11(1):59-64. |
| [7] | van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future[J]. Blood, 2018, 131(1):13-29. |
| [8] | Quarona V, Ferri V, Chillemi A, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche[J]. Ann N Y Acad Sci, 2015, 1335:10-22. |
| [9] | Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma[J]. Blood, 2016, 128(3):384-394. |
| [10] | Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology[J]. Physiol Rev, 2008, 88(3):841-886. |
| [11] | Sherbenou DW, Behrens CR, Su Y, et al. The development of potential antibody-based therapies for myeloma[J]. Blood Rev, 2015, 29(2):81-91. |
| [12] | Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy[J]. Nat Rev Immunol, 2010, 10(5):317-327. |
| [13] | de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J]. J Immunol, 2011, 186(3):1840-1848. |
| [14] | Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer[J]. Nat Rev Cancer, 2012, 12(4):278-87. |
| [15] | Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma[J]. MAbs, 2015, 7(2):311-321. |
| [16] | Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking[J]. J Immunol, 2016, 197(3):807-813. |
| [17] | Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma[J]. J Hematol Oncol, 2016, 9(1):51. |
| [18] | van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies[J]. Immunol Lett, 2018, 199:16-22. |
| [19] | Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma[J]. Front Immunol, 2018, 9:1228. |
| [20] | 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志, 2020, 59(5):341-346. |
| [21] | Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192):29-38. |
| [22] | Lamb YN. Daratumumab: A Review in Combination thera-py for transplant-eligible newly diagnosed multiple myeloma[J]. Drugs, 2020, 80(14):1455-1464. |
| [23] | Voorhees PM, Kaufman JL, Laubach J, et al. Daratumu-mab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood, 2020, 136(8):936-945. |
| [24] | Voorhees P, Rodriguez C, Reeves B, et al. Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Grifin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Muliple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)[J]. Blood, 2018, 132:151. |
| [25] | Bal S, Godby K, Chhabra S, et al. Impact of Autologous hematopoetic stem cell transplant (AHCT) on measurable residual disease(MRD) by next generation sequencing (NGS) in the setting of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) quadruplet induction[J]. Biol Blood Marrow Transplant, 2020, 26(3):S24. |
| [26] | Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218):132-141. |
| [27] | Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma[J]. Cancer, 2019, 125(14):2364-2382. |
| [28] | Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22):2104-2115. |
| [29] | 郭怀鹏, 康蕾, 刘聪, 等. Daratumumab在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta分析[J]. 临床血液学杂志, 2021, 34(11):795-801,806. |
| [30] | 刘进, 何海燕, 李璐, 等. 达雷妥尤单抗治疗复发/难治多发性骨髓瘤的疗效与安全性[J]. 中华血液学杂志, 2021, 42(1):27-32. |
| [31] | Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumu-mab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 78(6):518-528. |
/
| 〈 |
|
〉 |
